Cardiovascular Risk Associated With Concurrent Proton Pump Inhibitor and Clopidogrel Therapy: Is It Explained by Interaction With CYP2C19 Genotype?

被引：0
|
作者：
Carlquist, John F. [1 ]
Horne, Benjamin D. [1 ]
Huntinghouse, John A. [1 ]
Park, James J. [1 ]
Mower, Chrissa P. [1 ]
Schaefer, Katie [1 ]
Hall, Nathaniel L. [1 ]
Mathews, Katy D. [1 ]
May, Heidi T. [1 ]
Muhlestein, Joseph B. [1 ]
Anderson, Jeffrey L. [1 ]
机构：
[1] Univ Utah, Intermt Med Ctr, Murray, UT USA
来源：
CIRCULATION | 2009年 / 120卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S599 / S599
页数：1
相关论文
共 50 条
  • [1] CYP2C19 genotype and proton pump inhibitor associated visual disturbance
    Mörike, K
    Griese, EU
    Schwab, M
    Lutz, M
    Marx, C
    Müller-Oerlinghausen, B
    Gleiter, CH
    Schönhöfer, PS
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : R125 - R125
  • [2] CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections
    Bernal, Christiana J.
    Aka, Ida
    Carroll, Robert J.
    Coco, Joseph R.
    Lima, John J.
    Acra, Sari A.
    Roden, Dan M.
    Van Driest, Sara L.
    PEDIATRICS, 2019, 144 (06)
  • [3] CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections
    Gupta, Kunal
    PEDIATRICS, 2020, 145 (06)
  • [4] Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19
    Cardenas, Liliana
    Aymen Abdullah, Ali
    Jaramillo, Gabriela
    Cardenas, Paul
    Galvez, Gabriela
    Hidalgo, Fernando
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2023, 52 (03): : 134 - 137
  • [5] Dose of proton pump inhibitors and the CYP2C19 genotype
    Bertilsson, L
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 95 (01) : 1 - 1
  • [6] CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections Response
    Van Driest, Sara L.
    Bernal, Christiana J.
    PEDIATRICS, 2020, 145 (06)
  • [7] Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
    Ichikawa, Hitomi
    Sugimoto, Mitsushige
    Sugimoto, Ken
    Andoh, Akira
    Furuta, Takahisa
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (04) : 716 - 726
  • [8] Cardiovascular Risk Associated With Concurrent Proton Pump Inhibitor and Clopidogrel Therapy: How Much? How Specific?
    Hall, Nathaniel L.
    Mathews, Katy D.
    May, Heidi T.
    Bair, Tami L.
    Horne, Benjamin D.
    Carlquist, John F.
    Lappe, Donald L.
    Muhlestein, Joseph B.
    Anderson, Jeffrey L.
    CIRCULATION, 2009, 120 (18) : S422 - S422
  • [9] CYP2C19 GENOTYPE AND RESPONSE TO PROTON PUMP INHIBITOR THERAPY IN NAAyVE ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
    Gonzalez-Cordero, Pedro L.
    Rivas, Maria Dolores
    Arias, Angel
    Rodrigo, Luis
    Barrio, Jesus
    Nantes, Oscar
    Flores, Alexander
    Perona, Monica C.
    Rodriguez-Tellez, Manuel
    Zamorano, Jose
    Lucendo, Alfredo
    Molina-Infante, Javier
    GASTROENTEROLOGY, 2017, 152 (05) : S856 - S856
  • [10] Effect of Different Proton Pump Inhibitors on the Antiplatelet Activity of Clopidogrel in Relation to CYP2C19 Genotype Status
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Kodaira, Chise
    Nishino, Masafumi
    Yamade, Mihoko
    Uotani, Takahiro
    Ikuma, Mutsuhiro
    Umemura, Kazuo
    GASTROENTEROLOGY, 2010, 138 (05) : S469 - S469
12345